Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
N-acetylcysteine · 1 trial · 1 indication
Number of coughs will be measured by a 24-hour ambulatory cough monitoring system for the first 72 hours
| Arm | Type | Description |
|---|---|---|
| A N-acetylcysteine | EXPERIMENTAL | N-acetylcysteine |
| B Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| N-acetylcysteine | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Cold/URTI symptoms occurring no more than 4 days * cough due to a cold or acute viral (URTI) with an onset of no more than 3 days * cough frequency with specified cut-off Exclusion Criteria: * A subchronic, or chronic cough (cough duration \> 2 months) due to any condition o...
N-acetylcysteine is being studied for the treatment of the common cold associated with cough. It is a small molecule being developed by Novartis AG. The drug is currently in Phase 2 clinical development for this indication.
N-acetylcysteine is a small molecule. Its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential to treat the common cold associated with cough.
N-acetylcysteine is being developed by Novartis AG, a pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's efficacy in treating the common cold associated with cough.
N-acetylcysteine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of the common cold associated with cough.
N-acetylcysteine has one completed Phase 2 clinical trial with the identifier NCT02379637. This trial evaluated the efficacy of N-acetylcysteine in the treatment of the common cold and cough. The study enrolled 70 participants in Canada and was randomized, double-blind, and placebo-controlled.
N-acetylcysteine is commonly referred to as NAC. The clinical trial NCT02379637 uses the abbreviation NAC to refer to the drug. Both names refer to the same investigational compound being developed for the common cold associated with cough.